Jodi Parsons, Ph.D. Senior Director of Regulatory Affairs
Dr. Parsons joined DNS as head of Regulatory Affairs in June 2010, bringing 20+ years of experience in global pharmaceutical development of both drugs and biologics. Prior to her role at DNS, Dr. Parsons was Senior Director of Regulatory Affairs at Somaxon Pharmaceuticals, Inc., where she managed the lifecycle of early stage 505(b)(2) products directed toward treatment of impulse and movement disorders and addiction, and implemented regulatory strategy to support the registration of Silenor® for treatment of insomnia. At Elan Pharmaceuticals, Inc., Dr. Parsons served as regulatory project lead supporting global registration of Tysabri® in the treatment of multiple sclerosis and Crohn's disease, and development of natalizumab for treatment of rheumatoid arthritis and ulcerative colitis. Prior to this, Dr. Parsons assumed various roles of increasing responsibility within Development Chemistry and later Regulatory Affairs at Isis Pharmaceuticals, Inc., where she contributed to the development of antisense oligonucleotide therapeutics targeting CMV retinitis (Vitravene®), and various autoimmune diseases. Dr. Parsons holds a B.S. in Chemistry from the University of Miami and a Ph.D. in Chemistry from Emory University.